These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 381717)

  • 21. Activation of membrane phospholipase A by guinea pig lymphotoxin (GLT).
    Kobayashi Y; Sawada JI; Osawa T
    J Immunol; 1979 Mar; 122(3):791-4. PubMed ID: 312824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The indiction by complement of a change in KSCN-dissociable red cell membrane lipids.
    Giavedoni EB; Dalmasso AP
    J Immunol; 1976 Apr; 116(4):1163-9. PubMed ID: 1254965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
    Hänsch GM; Hammer CH; Mayer MM; Shin ML
    J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Release of phospholipids from complement-mediated lesions on the surface structure of Escherichia coli.
    Inoue K; Kinoshita T; Okada M; Akiyama Y
    J Immunol; 1977 Jul; 119(1):65-72. PubMed ID: 326965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of specific phospholipids on the antibody-complement-mediated killing of nucleated cells.
    Ohanian SH; Schlager SI; Yamazaki M; Ishida B
    J Immunol; 1979 Sep; 123(3):1014-9. PubMed ID: 469242
    [No Abstract]   [Full Text] [Related]  

  • 26. Release of phospholipids from liposomal model membrane damaged by antibody and complement.
    Kinoshita T; Inoue K; Okada M; Akiyama Y
    J Immunol; 1977 Jul; 119(1):73-6. PubMed ID: 559702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation.
    Vogt W; Schmidt G; Hinsch B
    Immunology; 1979 Jan; 36(1):139-43. PubMed ID: 422225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma membrane and intracellular lipid synthesis in tumor cells rendered resistant to humoral immune killing after treatment with hormones.
    Schlager SI; Ohanian SH
    J Natl Cancer Inst; 1980 Apr; 64(4):943-50. PubMed ID: 6988626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.
    Fries LF; Friedman HM; Cohen GH; Eisenberg RJ; Hammer CH; Frank MM
    J Immunol; 1986 Sep; 137(5):1636-41. PubMed ID: 3018078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of non-steroidal antiinflammatory drugs on some biological activities dependent on complement activation.
    Orsolini P; Milani MR; Velgi C
    Arzneimittelforschung; 1979; 29(2):179-81. PubMed ID: 375949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense.
    Ohanian SH; Schlager SI
    Crit Rev Immunol; 1981 Jan; 1(3):165-209. PubMed ID: 6174273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of different blood parameters for evaluation of complement activation during hemodialysis.
    Gardinali M; Cicardi M; Bergamaschini L; Frangi D; Franzinelli M; Anelli A; Brancaccio D; Agostoni A
    Trans Am Soc Artif Intern Organs; 1985; 31():42-4. PubMed ID: 3837483
    [No Abstract]   [Full Text] [Related]  

  • 33. The membrane attack pathway of complement.
    Esser AF
    Year Immunol; 1989-1990; 6():229-44. PubMed ID: 2701906
    [No Abstract]   [Full Text] [Related]  

  • 34. Blocking of the hemolytic expression of the classical complement sequence by products of complement activation via the alternate pathway. Materials responsible for the blocking phenomenon and their proposed mechanism of action.
    Koethe SM; Austen KF; Gigli I
    J Immunol; 1973 Feb; 110(2):390-400. PubMed ID: 4684033
    [No Abstract]   [Full Text] [Related]  

  • 35. Separate pathways of C activation by measles virus cytotoxic antibodies: subclass analysis and capacity of F(ab) molecules to activate C via the alternative pathway.
    Ehrnst A
    J Immunol; 1978 Sep; 121(3):1206-12. PubMed ID: 690438
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
    Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
    Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reaction of an activated complex of guinea-pig complement components, C56, with unsensitized erythrocytes and with erythrocytes carrying C3b molecule.
    Tamura N; Baba AS
    Immunology; 1976 Jul; 31(1):151-8. PubMed ID: 1027719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Progress in the knowledge of complement. I. Structure, activation and control of the complement system].
    Lesavre P; Leibowitch J
    Nouv Presse Med; 1979 Jun; 8(29):2385-7. PubMed ID: 493022
    [No Abstract]   [Full Text] [Related]  

  • 39. Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5.
    Goldlust MB; Shin HS; Hammer CH; Mayer MM
    J Immunol; 1974 Sep; 113(3):998-1007. PubMed ID: 4213402
    [No Abstract]   [Full Text] [Related]  

  • 40. Freeze-thaw activation of the complement attack phase: II. Comparison of convertase generated C--56 with C--56 generated by freezing and thawing.
    Dessauer A; Rother U; Rother K
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():83-8. PubMed ID: 6444196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.